Article Text
Statistics from Altmetric.com
- hydroxychloroquine
- lupus erythematosus, systemic
- epidemiology
- communicable diseases, imported
- autoimmune diseases
In vitro inhibition of the novel coronavirus, SARS-CoV-2, by hydroxychloroquine (HCQ) has triggered further exploration of the clinical efficacy of this drug in covid-19. Rheumatologists all over the world are analysing registries of patients with systemic lupus erythematosus (SLE) and other rheumatic diseases to look at the prevalence of covid-19 in patients who have been on HCQ. On coming across the title, ‘SLE, hydroxychloroquine and no SLE patients with covid-19: a comment’, we read it with interest. The authors say, “There are several thousands of patients with covid-19 worldwide. Nevertheless, there is no case of SLE with covid-19”. There is no mention of any reference or source to the claim. They go on to extrapolate, “Hence, hydroxychloroquine …